tsRNADisease

Entry Detail

General Information

Database ID:	TRD02187
Confidence:	High
Contents:	>> tsRNA Information >> tsRNA Association Statistics >> Disease Information >> Disease Association Statistics >> Evidence Support >> Reference

tsRNA Information

tsRNA Name:

AS-tDR-000076

tsRNA Type:

tRF-3

Amino acid and Anticodon:

GlyACC;ValAAC;ValCAC

Sequence:

ACCGGGCGGAAACACCA

Related Target:

Predicted Target:

External Links:

MINTbase ID:	tRF-17-08Q2B52
tRFdb ID:	tRFdb-3008a

tsRNA Association Statistics

Total Associated Disease Number:	9 More Information
Network: (Display the first 15 nodes)

Disease Information

	MeSH	Disease Ontology
Disease ID:	D066253	N/A
Disease Name:	Vascular Remodeling	N/A
Category:	MeSH	Disease Ontology
Type:	Pathological Conditions, Signs and Symptoms//Circulatory and Respiratory Physiological Phenomena	N/A
Define:	The active alterations of vascular wall structures, often leading to elevated VASCULAR RESISTANCE. It is associated with AGING; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; PREGNANCY; PULMONARY HYPERTENSION; and STROKE, but is also a normal part of EMBRYOGENESIS.	N/A
Alias:	N/A	N/A

Disease Association Statistics

Total Associated tsRNA Number:	24 More Information
Network: (Display the first 15 nodes)

Evidence Support

Strong Evidence:	RT-PCR//Western blot
Weak Evidence:	High-throughput sequencing

Reference

[1] PubMed ID:	35705912
Disease Name:	Vascular Remodeling
Tissue:	HASMCs
Dysfunction Pattern:	Up-Regulation
Validated Method:	RT-PCR//Western blot//High-throughput sequencing
Description:	AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 were increased in proliferative HASMCs and were mainly located in the nucleus.
Comparision:	Proliferative HASMC VS Quiescent HASMC
Mechanism:	Data Mining suggested that the four tsRNAs involved a variety of GO terms and pathways related to VSMC proliferation. AS-tDR-000067 promoted HASMC proliferation by suppressing p53 transcription in a promoter-targeted manner. AS-tDR-000076 accelerated HASMC proliferation by attenuating mitofusin 2 (MFN2) levels in a 3′-untranslated region (UTR)-targeted manner.